Impact of dose frequency on compliance and health outcomes: A literature review (1966-2006)

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 2, 2007, Pages 187-202

  Shi, Lizheng ^a   Hudges, Meredith ^a   Yurgin, Nicole ^b   Boye, Kristina S ^b  

^a TULANE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Clinical effectiveness; Compliance; Delayed action preparations; Dose frequency; Dose administration schedule; Dosing efficacy; Persistense; Safety

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INSULIN; ISOPHANE INSULIN; ISOSORBIDE 5 NITRATE; MEVINOLIN; NICARDIPINE; NICOTINIC ACID; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ORAL ANTIDIABETIC AGENT; OXYBUTYNIN; PACLITAXEL; PHENOBARBITAL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; SULFONYLUREA; TRANDOLAPRIL; UNINDEXED DRUG;

ADJUVANT THERAPY; ANEMIA; ANGINA PECTORIS; ANKYLOSING SPONDYLITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEX PARTIAL SEIZURE; CONTROLLED DRUG RELEASE; COUGHING; DETRUSOR DYSSYNERGIA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPILEPSY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY FAILURE; MAJOR DEPRESSION; MONOTHERAPY; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERITONEAL DIALYSIS; PROSTATE HYPERTROPHY; RESTLESS LEGS SYNDROME; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SLOW RELEASE FORMULATION; SOMNOLENCE; STABLE ANGINA PECTORIS; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

EID: 34247847931     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.2.187     Document Type: Review

References (81)

1. Heerdink ER, Urquhart J. Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf 11(6), 447-453 (2002).
2. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother. 55(5), 616-627 (2005).
3. Babazono A, Miyazaki M, Imatoh T et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. Int. J. Technol. Assess. Health Care 21(2), 228-233 (2005).
4. Hinkin CH, Castellon SA, Durvasula RS et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 59(12), 1944-1950 (2002).
5. Rothenbacher D, Ruter G, Brenner H. Prognostic value of physicians' assessment of compliance regarding all-cause mortality in patients with Type 2 diabetes: primary care follow-up study. BMC Fam. Pract. 7, 42 (2006).
6. Kogut SJ, Andrade SE, Willey C, Larrat EP. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol. Drug Saf. 13(9), 591-598 (2004).
7. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann. Pharmacother. 39(3), 508-515 (2005).
8. Kyngas H, Lahdenpera T. Compliance of patients with hypertension and associated factors. J. Adv. Nurs. 29(4), 832-839 (1999).
9. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23, 637-651 (1997).
10. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63(12), 1121-1128 (2002).
11. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Edu. 25(4), 531-532, 535, 537-538 (1999).
12. Wertheimer A, Santella T, Finestone A, Levy R. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv. Ther. 22(6), 559-577 (2005).
13. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23, 1296-1310 (2001).
14. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin. Ther. 25(8), 2307-2335 (2003).
15. Morris AD. Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ. 29(3), 440-446, 448, 450-453 (2003).
16. Porter A. Daily regimen and compliance with treatment: literature before 1980 should not have been ignored. Br. Med. J. 324, 425 (2002).
17. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carte A. Electronic pill boxes in the evaluation of antihypertensive compliance: comparison of once daily versus twice daily regimen. Am. J. Hypertens. 13, 184-190 (2000).
18. Boissel JP, Meillard O, Perrin-Fayolle E et al. Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Eur. J. Clin. Pharmacol. 50(1-2), 63-67 (1996).
19. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J. Int. Med Res. 22 (5), 266-272 (1994).
20. Eisen S, Miller D, Woodward R, Spitzangel E, Pryzbeck T. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150(9), 1881-1884 (1990).
21. Gabriel M, Gagnon J, Bryan C. Improved patient compliance through use of a daily drug reminder chart. Am. J. Public Health 67(10), 968-969 (1977).
22. Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. J. Cardiol. 13(10), 914-920 (1997).
23. Mengden T, Binswanger B, Spuhler T, Weisser B, Vetter W. The use of setf-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J. Hypertens. 11(12), 1403-1411 (1993).
24. Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacother. 18(4), 836-839 (1998).
25. Sramek JJ, Cutler NR, Seifert RD, Luna AD. Compliance in hypertension: daily v. twice daily. Am. J. Hypertens. 6, 1063 (1993).
26. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur. J. Clin. Pharmacol. 47(6), 477-481 (1995).
27. Kruse W, Rampier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int. J. Clin. Pharmacol. Ther. 32(9), 452-457 (1994).
28. Rubenfire M and IMPACT of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am. J. Cardiol, 94(3), 306-311 (2004).
29. Tanabe K, Serruys P, Grube E et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in slow-release polymer formulation. Circulation 107(4), 559-564 (2003).
30. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four-h duration of action. J. Hypertens. Suppl. 12(8), S67-S71 (1994).
31. Weidler D, Wallin JD, Cook E, Dillard D, Lewin A. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. J. Clin. Pharmacol. 320), 444-449 (1992).
32. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am. J. Manag. Care 4(11), 1563-1568 (1998).
33. National Guidelines Research and Development Unit. Essential hypertension: managing adult patients in primary care. Evidence-Based Clinical Practice Guideline. (2004).
34. Pearson M. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. A Clinical Guideline for the NHS in England and Wales (2003).
35. Dezii C, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South Med. J. 95(1), 68-71 (2002).
36. Kardas P. The DIACOM (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of Type 2 diabetes). Diabetes Obes. Metab. 7, 722-728 (2005).
37. Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ. 21(1), 52-57 (1995).
38. Paes A, Bakker A. Soe-Agnie C. Impact of dosage frequency on patient compliance. Diabetes Care 20(10), 1512-1517 (1997).
39. Pullar T, Bitwell A. Wiles P, Hay A, Feely M. Use of pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin. Pharmacol. Ther. 44(5), 540-545 (1988).
40. Morris A. Addressing the dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ. 29(3), 440-453 (2003).
41. Coates P, Ismail I, Luzio S et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in Type II diabetic subjects. Diabet. Med. 12(3), 235-239 (1995).
42. Taylor R, Foster B, Kyne-Girebalski D, Vanderpump M. Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life. Diabet. Med. 11(6), 551-557 (1994).
43. Del Vecchio L, Villa G, Carraro G et al. Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin. G. Ital, Nefrol. 21(3), 259-266 (2004).
44. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol. Dial. Transplant. 18(2), 362-369 (2003).
45. MacDougall I, Matcham J, Gray S. NESP. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol. Dial. Transplant. 18(3), 576-581 (2003).
46. Vanrenterghem Y, Barany P. Mann J et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 62(6) 2167-2175 (2002).
47. O'Leary M, Erickson J, Smith C, McDermott C, Horton J, Chancellor M. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J. Spinal Cord Med. 26(2), 159-162 (2003).
48. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur. Urol. 37(3), 306-313 (2000).
49. van Kerrebrocck P, Jardin A, Van Cangh P, Laval K, ALFORTI Study Group. Long-term safety and efficacy of once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol. 41(1), 54-60 (2002).
50. Michel M. A benefit-risk assessment of extended-release oxybutynin. Drug Saf. 25(12), 867-876 (2002).
51. Rovner E, Wein A. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur. Urol. 41(1), 6-14 (2002).
52. Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 15(1), 111-117 (2005).
53. Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J. Clin. Psychiatry 61(12), 928-932 (2000).
54. Cramer J, Vachon L, Desforges C, Sussman N. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 36(11), 1111-1117 (1994).
55. Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int. Clin. Psychopharmacol. 13(1), 11-17 (1998).
56. Rickels K, Smith W, Glaudin V, Amsterdam J, Weise C, Setlle G. Comparison of two dosage regimens of fluoxetine in major depression. J. Clin. Psychiatry 46(3 Pt 2), 38-41 (1985).
57. Sachdeo R, Leroy R, Krauss G et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch. Neurol. 54(5), 595-601 (1997).
58. Stein M, Pollack M, Bystritsky A, Kelsey J, Mangano R. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 177(3), 280-288 (2005).
59. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 261(22), 3273-3277 (1989). Erratum appears in 262(11), 1472 (1989).
60. Diaz E, Neuse E, Sullivan M, Pearsall H, Woods S. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 65(3), 354-360 (2004).
61. Doughty J, Baker G, Jacoby A, Lavallo V. Compliance and satisfaction with switching from immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 4(6), 710-716 (2003).
62. Hiratsuka S, Kumano H, Katayama J, Hishinuma T, Yamauchi Y, Mizugaki M. Drug Compliance Scale. II. Psychological factors affecting drug compliance in the department of psychosomatic medicine. J. Pharm. Soc. Japan 120(2), 230-237 (2000).
63. Saletu-Zyhlarz G, Anderer P. Arnold O, Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology 48(4), 194-208 (2003).
64. Francis G. Benefit-risk assessment of interferon-β therapy for relapsing multiple sclerosis. Expert Opin. Drug Saf. 3(4), 289-303 (2004).
65. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD002127 (2006).
66. Love R, Conley R. Long-acting risperidone injection. Am. J. Health Syst. Pharm. 61(17), 1792-1800 (2004).
67. Rickels K. Alprazolam extended-release in panic disorder. Expert Opin. Pharmacother. 5(7), 1599-1611 (2004).
68. Weber C JR, Sather M, Mace D. Improving patient compliance through use of single daily dosages. Hosp. Pharm. 12(10), 508-510 (1977).
69. Campion G, Lebsack M, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 39(7), 1092-1101 (1996).
70. Lehtinen K, Kaarela K, Makisara P, Holttinen K, Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. Br. J. Rheumatol. 23(1), 52-56 (1984).
71. Molina-Lopez J. Fentiazac in osteoarthritis: comparison of BID and QID regimens. Clin. Ther. 5(5), 462-471 (1983).
72. Trenkwalder C, Collado Seidel V, Kazenwadel J et al. One-year treatment with standard and sustained-release levodpa: appropriate long-term treatment of restless legs syndrome? Mov. Disord. 18(10), 1184-1189 (2003).
73. Belcon M, Haynes R, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum. 27(11), 1227-1233 (1984).
74. Fischer R. Compliance-oriented prescribing: simplifying drug regimens. J. Fam. Pract. 10(3), 427-435 (1980).
75. Fischer R. Frequency of drug-administration. A prime factor in patient compliance and health care cost. J. Miss. State Med. Assoc. 19(9), 161-167 (1978).
76. Haynes R, Sackett D, Taylor W, Roberts R, Johnson A. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin. Pharmacol. Ther. 22(2), 125 (1977).
77. Iskedjian M, Einarson T, MacKeigan L, Shearn Addis A, Mittmann N, Ilersich A. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther. 24(2), 302-316 (2002).
78. Bass D, Prevo M, Waxman D. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form. Drug Saf. 25(14), 1021-1033 (2002).
79. Florence A, Jani P. Novel oral drug formulations. Their potential in modulating adverse effects. Drug Saf. 10(3), 233-266 (1994).
80. Cramer M, Saks S. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 5(6), 482-504, (1994).
81. Shireman TI, Svarstad BL, Sweeney JK. Validity of claims data fbr long-acting injectable medications. J. Pharmacoepidemiol. 7(2), 41-55 (1999).